Last reviewed · How we verify

IM862 — Competitive Intelligence Brief

IM862 (IM862) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulatory peptide. Area: Oncology.

phase 3 Immunomodulatory peptide IL-2 pathway / T-cell activation Oncology Small molecule Live · refreshed every 30 min

Target snapshot

IM862 (IM862) — Cytran. IM862 is an immunomodulatory agent that enhances immune function through interleukin-2 (IL-2) pathway activation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IM862 TARGET IM862 Cytran phase 3 Immunomodulatory peptide IL-2 pathway / T-cell activation
Thymosin-α1 Thymosin-α1 Sun Yat-sen University phase 3 Immunomodulatory peptide

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulatory peptide class)

  1. Cytran · 1 drug in this class
  2. Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IM862 — Competitive Intelligence Brief. https://druglandscape.com/ci/im862. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: